A company with laboratories in Shenzhen and San Diego that makes low-cost multi-cancer blood tests from protein markers and shallow DNA sequencing.
SeekIn, founded in 2017 according to its website, with a San Diego contact address and research affiliations in Shenzhen, makes OncoSeek, an artificial intelligence test on seven protein tumour markers aimed at low- and middle-income countries, and SeekInCare, which adds shallow whole-genome sequencing of cell-free DNA. Its studies are published with Sun Yat-sen Memorial Hospital and Johns Hopkins collaborators.
SeekIn's low-cost protein blood test for 14 cancers, designed for countries that cannot afford DNA sequencing; it finds about six in ten cancers but flags about one in twelve people without cancer.
SeekIn's multi-omic blood test that adds DNA sequencing to its protein test; in published studies it found about six to seven in ten cancers and about four in ten at stage I.
Consistent across sites and platforms, with the same limit as before: specificity too low for population screening without a second test.
One of few multi-cancer tests with a stage I figure above one in three, from a case-control set; the prospective figures rest on few cancers.
Cheap and runs on hospital analysers, but at about 93% specificity a screening programme would generate many false alarms for each cancer found.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/